Literature DB >> 18836420

Caveolin-1 expression in human breast lobular cancer progression.

Giuseppe Perrone1, Vittorio Altomare, Mariagiovanna Zagami, Sergio Morini, Tommaso Petitti, Cleonice Battista, Andrea Onetti Muda, Carla Rabitti.   

Abstract

Caveolin-1 is the principal structural protein of caveolae, and caveolin-1 gene plays a role as a tumour suppressor gene in human mammary cancer-derived cells. However, limited data are available concerning caveolin-1 expression in human breast cancer tissue. We evaluated caveolin-1 expression in normal lobular epithelial cells and in the whole human lobular neoplasia spectrum disease, with the aim to examine differences of caveolin-1 expression in human lobular neoplasia progression. We selected 147 cases of pure lobular lesions, ie lobular intraepithelial neoplasia and invasive lobular carcinoma, from 112 patients. Presence of caveolin-1 was evaluated by immunohistochemistry. Among 81 lobular intraepithelial neoplasia lesions studied, 43% were associated with invasive lobular carcinoma, with positive correlation between lobular intraepithelial neoplasia grade and presence of invasive component (P=0.01). In total, 64% of lobular lesions were positive for caveolin-1 (81% lobular intraepithelial neoplasia and 42% invasive lobular carcinoma), and a significant difference in terms of caveolin-1 expression was present between lobular intraepithelial neoplasia and invasive lobular carcinoma (P=0.0001). Variations in caveolin-1 expression were evident among the different lobular intraepithelial neoplasia grades (91% grade 1, 68% grade 2, 35% grade 3); the difference was significant comparing lobular intraepithelial neoplasia grade 3 vs 1 (P=0.0001) and grade 3 vs 2 (P=0.007) but not grade 1 vs 2. Furthermore, significant differences were found between lobular intraepithelial neoplasia grades 1 and 2 vs invasive lobular carcinoma (P=0.0001), but not between lobular intraepithelial neoplasia grade 3 and invasive lobular carcinoma (P=0.196). In conclusion, variations of caveolin-1 expression may have an important role in the progression of human breast lobular cancer; in addition, they confirm the powerful clinical impact of the lobular intraepithelial neoplasia classification for lobular intraepithelial neoplasia, supporting the direct origin of invasive lobular carcinoma from clonal expansion of the lobular intraepithelial neoplasia lesions cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836420     DOI: 10.1038/modpathol.2008.154

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

Review 1.  Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer.

Authors:  Wang Shan-Wei; Xu Kan-Lun; Ruan Shu-Qin; Zhao Li-Li; Chen Li-Rong
Journal:  Breast Care (Basel)       Date:  2012-12       Impact factor: 2.860

2.  Proteomic profiling of lipid rafts in a human breast cancer model of tumorigenic progression.

Authors:  Joseph A Caruso; Paul M Stemmer
Journal:  Clin Exp Metastasis       Date:  2011-05-01       Impact factor: 5.150

3.  Caveolin-1 induces formation of membrane tubules that sense actomyosin tension and are inhibited by polymerase I and transcript release factor/cavin-1.

Authors:  Prakhar Verma; Anne G Ostermeyer-Fay; Deborah A Brown
Journal:  Mol Biol Cell       Date:  2010-04-28       Impact factor: 4.138

4.  Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma.

Authors:  Cristiana Pistol Tanase; Simona Dima; Mihaela Mihai; Elena Raducan; Mihnea Ioan Nicolescu; Lucian Albulescu; Bogdan Voiculescu; Traian Dumitrascu; Linda Maria Cruceru; Mircea Leabu; Irinel Popescu; Mihail Eugen Hinescu
Journal:  J Mol Histol       Date:  2009-01-22       Impact factor: 2.611

5.  Expression of caveolin-1 in tongue squamous cell carcinoma by quantum dots.

Authors:  J Xue; H Chen; L Diao; X Chen; D Xia
Journal:  Eur J Histochem       Date:  2010-04-14       Impact factor: 3.188

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.